Holen Sie sich die Stockscreener-App
726.21
4.86%
33.63
Vorhandelsmarkt:
726.21
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
How Investors May Respond To Regeneron (REGN) Lynozyfic Multiple Myeloma Data And Frontline Oncology Ambitions - simplywall.st
Wells Fargo & Company Issues Positive Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Wells Fargo Raises Price Target for Regeneron (REGN) to $745 | REGN Stock News - GuruFocus
How Is The Market Feeling About Regeneron Pharmaceuticals Inc? - Benzinga
Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial - Reuters
Transcript : Regeneron Pharmaceuticals, Inc.Special Call - marketscreener.com
Stempoint Capital LP Purchases New Shares in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Wells Fargo Adjusts PT on Regeneron Pharmaceuticals to $745 From $700, Maintains Equalweight Rating - marketscreener.com
iSAM Funds UK Ltd Acquires New Shares in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
State Street Corp Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Diadema Partners LP Trims Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Climbs Back After a Year of Regulatory, Manufacturing Misery - BioSpace
Regeneron (REGN): Revisiting Valuation After a Short-Term Pullback and Longer-Term Shareholder Weakness - simplywall.st
Kymera Keeps Rising With More Positive Dupixent-In-A-Pill Data - Citeline News & Insights
Regeneron Pharmaceuticals' Upcoming Melanoma Data Likely to Look Competitive, RBC Says - marketscreener.com
ASH takeaways: Regeneron unveils new data on blood cancer drugs, touts hematology pipeline - Medical Marketing and Media
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MSN
Here's Why You Should Retain OPKO Health Stock in Your Portfolio Now - TradingView
Ossiam Sells 22,234 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Stock Slides 11% With A 8-Day Losing Spree - Trefis
Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention (NASDAQ:REGN) - Seeking Alpha
Regeneron's (REGN) Recovery and Dupixent Strength Support BMO's Outperform Rating - Finviz
Regeneron’s (REGN) recovery and Dupixent strength support BMO’s outperform rating - MSN
Regeneron’s (REGN) Recovery and Dupixent Strength Support BMO’s Outperform Rating - Insider Monkey
Why Is Kymera Therapeutics Stock Skyrocketing Monday?Kymera Therapeutics (NASDAQ:KYMR) - Benzinga
Natixis Purchases 2,751 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Tessera Therapeutics Showcases New Preclinical Data Demonstrating Progress of In Vivo Programs for Sickle Cell Disease and T Cell Therapies at the 67th American Society of Hematology Annual Meeting - GlobeNewswire Inc.
Anti-VEGF Market Growth Outlook: USD 41.3 Billion by 2035 With - openPR.com
California Public Employees Retirement System Sells 158,734 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
14 Best US Stocks to Buy for Long Term - Insider Monkey
Regeneron (REGN) Showcases Promising Trial Data for Lynozyfic in Multiple Myeloma - GuruFocus
Regeneron Reports Promising Results from LINKER-MM4 Trial of Lynozyfic™ for Newly Diagnosed Multiple Myeloma - Quiver Quantitative
Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment - The Manila Times
Federated Hermes Inc. Acquires 204,045 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Understanding Momentum Shifts in (REGN) - news.stocktradersdaily.com
Can Regeneron Pharmaceuticals Stock Recover If Markets Fall? - Trefis
Does Regeneron’s Choppy 2025 Share Price Reflect Its Long Term Growth Potential? - Yahoo Finance
Regeneron's experimental therapy combo effective in untreated cancer patients - Reuters
Marshall Wace LLP Has $125.95 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Panagora Asset Management Inc. - MarketBeat
First Trust Advisors LP Increases Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Baird Financial Group Inc. Grows Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Amundi - MarketBeat
Canaccord Genuity Group Forecasts Strong Price Appreciation for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock - MarketBeat
Is Regeneron Still Attractive After Recent Pipeline Milestones and Valuation Upside Signals? - simplywall.st
BMO Capital Markets Issues Positive Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Can Regeneron Pharmaceuticals Inc. stock maintain growth trajectoryJuly 2025 Retail & Free Safe Entry Trade Signal Reports - Newser
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Guggenheim Capital LLC - MarketBeat
Invesco Ltd. Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Why Regeneron Pharmaceuticals Inc. (RGO) stock is listed among top recommendationsOptions Play & Community Driven Trade Alerts - Newser
Dodge & Cox Acquires 1,502,198 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Holdings Lowered by Epoch Investment Partners Inc. - MarketBeat
Will Regeneron Pharmaceuticals Inc. (RGO) stock profit from fiscal stimulus2025 Retail Activity & Daily Momentum Trading Reports - Newser
How Regeneron Pharmaceuticals Inc. (RGO) stock responds to job market shiftsJuly 2025 Trends & Weekly Setup with ROI Potential - Newser
Can Regeneron Pharmaceuticals Inc. (RGO) stock sustain institutional flowsJuly 2025 Update & High Accuracy Trade Alerts - Newser
With Regeneron Pharmaceuticals Stock Sliding, Have You Assessed The Risk? - Trefis
Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory - Finviz
Citi Healthcare In Brief: Launch Trajectories Under Scrutiny - Citeline News & Insights
Can Regeneron Pharmaceuticals Inc. stock sustain institutional interestMarket Volume Report & Weekly Top Stock Performers List - Newser
Market Whales and Their Recent Bets on REGN Options - Benzinga
REGN: BMO Capital Raises Price Target and Maintains Outperform R - GuruFocus
BMO Capital raises Regeneron Pharma stock price target to $850 on Dupixent growth - Investing.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Lowered to "Equal Weight" at Morgan Stanley - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Lifted by Lido Advisors LLC - MarketBeat
How Does Regeneron Pharmaceuticals Stock Stack Up Against Its Peers? - Trefis
0.08%
2.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):